CU24647B1 - Moduladores del receptor nmda heteroaromático - Google Patents
Moduladores del receptor nmda heteroaromáticoInfo
- Publication number
- CU24647B1 CU24647B1 CU2021000013A CU20210013A CU24647B1 CU 24647 B1 CU24647 B1 CU 24647B1 CU 2021000013 A CU2021000013 A CU 2021000013A CU 20210013 A CU20210013 A CU 20210013A CU 24647 B1 CU24647 B1 CU 24647B1
- Authority
- CU
- Cuba
- Prior art keywords
- heteroaromatic
- modulators
- nmda receptor
- formula
- psychiatric
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
<p>La presente invención se refiere a un compuesto de Ia fórmula:</p> <p>ESPACIO PARA LA FORMULA</p> <p>útil en el tratamiento de trastornos psiquiátricos, neurológicos y del neurodesarrollo, así como enfermedades del sistema nervioso.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862714100P | 2018-08-03 | 2018-08-03 | |
| PCT/US2019/044814 WO2020086136A2 (en) | 2018-08-03 | 2019-08-02 | Heteroaromatic nmda receptor modulators and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20210013A7 CU20210013A7 (es) | 2021-09-07 |
| CU24647B1 true CU24647B1 (es) | 2023-02-13 |
Family
ID=69228330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2021000013A CU24647B1 (es) | 2018-08-03 | 2019-08-02 | Moduladores del receptor nmda heteroaromático |
Country Status (37)
| Country | Link |
|---|---|
| US (5) | US10584131B2 (es) |
| EP (2) | EP4223760B1 (es) |
| JP (1) | JP7319369B2 (es) |
| KR (1) | KR102797968B1 (es) |
| CN (1) | CN112513047B (es) |
| AR (1) | AR115905A1 (es) |
| AU (1) | AU2019368147B2 (es) |
| BR (1) | BR112021001967A2 (es) |
| CA (1) | CA3108519A1 (es) |
| CL (1) | CL2021000294A1 (es) |
| CO (1) | CO2021002898A2 (es) |
| CR (1) | CR20210125A (es) |
| CU (1) | CU24647B1 (es) |
| CY (1) | CY1126144T1 (es) |
| DK (1) | DK3830092T3 (es) |
| DO (1) | DOP2021000025A (es) |
| EA (1) | EA202190431A1 (es) |
| EC (1) | ECSP21014902A (es) |
| ES (2) | ES3039982T3 (es) |
| FI (1) | FI3830092T3 (es) |
| HR (1) | HRP20230774T1 (es) |
| HU (1) | HUE062566T2 (es) |
| IL (1) | IL280474B2 (es) |
| JO (1) | JOP20210020A1 (es) |
| LT (1) | LT3830092T (es) |
| MA (1) | MA53351B1 (es) |
| MX (1) | MX2021001367A (es) |
| PE (1) | PE20210948A1 (es) |
| PH (1) | PH12021550242A1 (es) |
| PL (1) | PL3830092T3 (es) |
| PT (1) | PT3830092T (es) |
| RS (1) | RS64359B1 (es) |
| SG (1) | SG11202101125VA (es) |
| SI (1) | SI3830092T1 (es) |
| TW (1) | TWI833783B (es) |
| WO (1) | WO2020086136A2 (es) |
| ZA (1) | ZA202101273B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2950348T3 (es) | 2015-12-09 | 2023-10-09 | Novartis Ag | Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos |
| PL3386591T3 (pl) * | 2015-12-09 | 2021-02-22 | Novartis Ag | Heteroaromatyczne modulatory receptorów nmda i ich zastosowania |
| EP3558318B1 (en) | 2016-12-22 | 2023-12-20 | Novartis AG | Nmda receptor modulators and uses thereof |
| RS64359B1 (sr) | 2018-08-03 | 2023-08-31 | Novartis Ag | Heteroaromatični modulatori nmda receptora i njihove upotrebe |
| WO2025019109A1 (en) * | 2023-07-17 | 2025-01-23 | Neumora Therapeutics, Inc. | Modulators of nmda receptors and related products and methods |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2358891A1 (fr) | 1976-07-22 | 1978-02-17 | Yamanouchi Pharma Co Ltd | Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires |
| FR2549834B1 (fr) | 1983-07-25 | 1985-10-18 | Sanofi Sa | Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques |
| US4921854A (en) | 1986-12-30 | 1990-05-01 | Egis Gyogyszergyar | Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds |
| US5298502A (en) | 1988-12-12 | 1994-03-29 | Fmc Corporation | Method and composition for photodynamic treatment and detection of tumors |
| AU6643694A (en) | 1993-05-21 | 1994-12-20 | Pentapharm Ag | 3-(mercaptoalkyl)- or 3-(alkylthioalkyl)- pyrimidin-2,4(1h, 3h)-diones |
| CA2257950A1 (en) | 1996-06-28 | 1998-01-08 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
| US6339093B1 (en) | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| WO2002000629A1 (en) | 2000-06-26 | 2002-01-03 | Merck & Co., Inc. | Iminopyrimidine nmda nr2b receptor antagonists |
| WO2003024955A2 (en) | 2001-09-18 | 2003-03-27 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
| AR038118A1 (es) | 2002-01-14 | 2004-12-29 | Upjohn Co | Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales |
| US7005432B2 (en) | 2002-05-16 | 2006-02-28 | Hoffman-La Roche Inc. | Substituted imidazol-pyridazine derivatives |
| RU2378258C2 (ru) | 2004-07-13 | 2010-01-10 | Ф. Хоффманн-Ля Рош Аг | Производные сульфонамида |
| TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| US8618115B2 (en) | 2005-10-26 | 2013-12-31 | Bristol-Myers Squibb Company | Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them |
| JP5256202B2 (ja) | 2006-09-11 | 2013-08-07 | エム・エス・ディー・オス・ベー・フェー | キナゾリノンおよびイソキノリノンアセトアミド誘導体 |
| WO2008033757A2 (en) | 2006-09-11 | 2008-03-20 | N.V. Organon | 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives |
| CA2672893C (en) | 2006-12-15 | 2016-02-23 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
| EP1939187A1 (en) | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
| CA2677296A1 (en) | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Therapeutic agents |
| US9034907B2 (en) | 2007-04-18 | 2015-05-19 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2008138126A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
| WO2009025784A1 (en) | 2007-08-21 | 2009-02-26 | Merck & Co., Inc. | Heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| JP5425891B2 (ja) | 2008-05-01 | 2014-02-26 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュイン調節薬としてのキノリンおよび関連する類似体 |
| MX2010012961A (es) | 2008-05-29 | 2011-03-03 | Sirtris Pharmaceuticals Inc Star | Imidazopiridina y analogos relacionados como moduladores de sirtuina. |
| EP2138494A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
| AU2009266889B2 (en) | 2008-07-03 | 2013-05-02 | Glaxosmithkline Llc | Benzimidazoles and related analogs as sirtuin modulators |
| CN101628913B (zh) | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| CN102227420B (zh) | 2008-09-29 | 2015-06-24 | 西特里斯药业公司 | 作为沉默调节蛋白调节剂的喹唑啉酮、喹诺酮和相关的类似物 |
| EA020460B1 (ru) | 2009-01-12 | 2014-11-28 | Пфайзер Лимитед | Производные сульфонамида |
| WO2010111573A1 (en) | 2009-03-27 | 2010-09-30 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| EP2264035A1 (en) | 2009-06-04 | 2010-12-22 | Merz Pharma GmbH & Co. KGaA | Glycine B antagonists |
| TW201116532A (en) | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| AU2010305825A1 (en) | 2009-10-13 | 2012-04-19 | Merck Sharp & Dohme B.V. | Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor |
| US9290507B2 (en) | 2010-03-26 | 2016-03-22 | Boehringer Ingelheim International Gmbh | B-RAF kinase inhibitors |
| EP2552907B1 (en) | 2010-03-26 | 2014-10-22 | Boehringer Ingelheim International GmbH | Pyridyltriazoles |
| CA2805724A1 (en) | 2010-07-16 | 2012-01-19 | Rockefeller University | Oxadiazolo[3,2-a]pyrimidines and thiadiazolo[3,2-a]pyrimidines |
| US9394290B2 (en) | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| US20120165330A1 (en) | 2010-12-22 | 2012-06-28 | Sirtris Pharmaceuticals, Inc. | Quinazolinone and related analogs as sirtuin modulators |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| ES2648820T3 (es) | 2011-05-10 | 2018-01-08 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de los canales de sodio |
| WO2013048928A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| US8993557B2 (en) | 2011-09-30 | 2015-03-31 | Bristol-Myers Squibb Company | Pyridinedione carboxamide inhibitors of endothelial lipase |
| WO2013048942A1 (en) | 2011-09-30 | 2013-04-04 | Bristol-Myers Squibb Company | Quinolinone carboxamide inhibitors of endothelial lipase |
| CN102336768A (zh) | 2011-10-24 | 2012-02-01 | 中国科学院上海有机化学研究所 | N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途 |
| EP3628320B1 (en) | 2011-11-11 | 2022-03-16 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| JP6092897B2 (ja) | 2012-02-10 | 2017-03-08 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| US9278973B2 (en) | 2012-10-25 | 2016-03-08 | Bioenergenix Llc | Heterocyclic compounds for the inhibition of PASK |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| WO2014179144A1 (en) | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
| KR102272606B1 (ko) | 2013-06-28 | 2021-07-05 | 베이진 엘티디 | Raf 키나아제 및/또는 raf 키나아제 이량체 저해제로서 융합 트리시클릭 우레아 화합물 |
| WO2015007453A1 (en) | 2013-07-15 | 2015-01-22 | Syngenta Participations Ag | Microbiocidal heterobicyclic derivatives |
| AR097795A1 (es) | 2013-09-26 | 2016-04-13 | Mnemosyne Pharmaceuticals Inc | Derivados de n-arilmetilo sulfonamida como moduladores negativos de nr2a |
| RS58047B1 (sr) | 2013-10-11 | 2019-02-28 | Hoffmann La Roche | Tiazolopirimidinoni kao modulatori aktivnosti nmda receptora |
| WO2015064714A1 (ja) | 2013-10-31 | 2015-05-07 | 国立大学法人東京大学 | オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体 |
| CN103664877A (zh) | 2013-12-25 | 2014-03-26 | 重庆医药工业研究院有限责任公司 | 一种喹啉衍生物、其制备方法和应用 |
| EP3191459A1 (en) | 2014-09-05 | 2017-07-19 | AbbVie Deutschland GmbH & Co. KG | Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases |
| WO2016081649A1 (en) * | 2014-11-18 | 2016-05-26 | Emory University | Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto |
| RU2717665C2 (ru) | 2015-04-15 | 2020-03-24 | Ф. Хоффманн-Ля Рош Аг | Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата |
| CN108601814A (zh) | 2015-10-16 | 2018-09-28 | 西北大学 | 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合 |
| ES2950348T3 (es) | 2015-12-09 | 2023-10-09 | Novartis Ag | Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos |
| PL3386591T3 (pl) | 2015-12-09 | 2021-02-22 | Novartis Ag | Heteroaromatyczne modulatory receptorów nmda i ich zastosowania |
| WO2017188694A1 (ko) | 2016-04-25 | 2017-11-02 | 이뮤노메트테라퓨틱스 인코포레이티드 | 질소를 포함하는 헤테로아릴 화합물 및 이의 용도 |
| WO2018026371A1 (en) | 2016-08-04 | 2018-02-08 | Sunovion Pharmaceuticals Inc. | Dual nav1.2/5ht2a inhibitors for treating cns disorders |
| EP3558318B1 (en) | 2016-12-22 | 2023-12-20 | Novartis AG | Nmda receptor modulators and uses thereof |
| TWI821200B (zh) | 2017-09-27 | 2023-11-11 | 美商英塞特公司 | Tam抑制劑之鹽 |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| RS64359B1 (sr) | 2018-08-03 | 2023-08-31 | Novartis Ag | Heteroaromatični modulatori nmda receptora i njihove upotrebe |
-
2019
- 2019-08-02 RS RS20230563A patent/RS64359B1/sr unknown
- 2019-08-02 EA EA202190431A patent/EA202190431A1/ru unknown
- 2019-08-02 MA MA53351A patent/MA53351B1/fr unknown
- 2019-08-02 HR HRP20230774TT patent/HRP20230774T1/hr unknown
- 2019-08-02 WO PCT/US2019/044814 patent/WO2020086136A2/en not_active Ceased
- 2019-08-02 EP EP23165151.4A patent/EP4223760B1/en active Active
- 2019-08-02 ES ES23165151T patent/ES3039982T3/es active Active
- 2019-08-02 SG SG11202101125VA patent/SG11202101125VA/en unknown
- 2019-08-02 LT LTEPPCT/US2019/044814T patent/LT3830092T/lt unknown
- 2019-08-02 CA CA3108519A patent/CA3108519A1/en active Pending
- 2019-08-02 EP EP19876025.8A patent/EP3830092B1/en active Active
- 2019-08-02 JP JP2021529249A patent/JP7319369B2/ja active Active
- 2019-08-02 CR CR20210125A patent/CR20210125A/es unknown
- 2019-08-02 KR KR1020217006300A patent/KR102797968B1/ko active Active
- 2019-08-02 PL PL19876025.8T patent/PL3830092T3/pl unknown
- 2019-08-02 AR ARP190102209A patent/AR115905A1/es not_active Application Discontinuation
- 2019-08-02 CU CU2021000013A patent/CU24647B1/es unknown
- 2019-08-02 HU HUE19876025A patent/HUE062566T2/hu unknown
- 2019-08-02 FI FIEP19876025.8T patent/FI3830092T3/fi active
- 2019-08-02 BR BR112021001967-7A patent/BR112021001967A2/pt unknown
- 2019-08-02 PT PT198760258T patent/PT3830092T/pt unknown
- 2019-08-02 AU AU2019368147A patent/AU2019368147B2/en active Active
- 2019-08-02 IL IL280474A patent/IL280474B2/en unknown
- 2019-08-02 MX MX2021001367A patent/MX2021001367A/es unknown
- 2019-08-02 PE PE2021000151A patent/PE20210948A1/es unknown
- 2019-08-02 ES ES19876025T patent/ES2951872T3/es active Active
- 2019-08-02 JO JOP/2021/0020A patent/JOP20210020A1/ar unknown
- 2019-08-02 SI SI201930580T patent/SI3830092T1/sl unknown
- 2019-08-02 CN CN201980051645.9A patent/CN112513047B/zh active Active
- 2019-08-02 US US16/530,274 patent/US10584131B2/en active Active
- 2019-08-02 TW TW108127473A patent/TWI833783B/zh active
- 2019-08-02 DK DK19876025.8T patent/DK3830092T3/da active
- 2019-11-08 US US16/678,806 patent/US10752633B2/en active Active
-
2021
- 2021-02-01 PH PH12021550242A patent/PH12021550242A1/en unknown
- 2021-02-02 DO DO2021000025A patent/DOP2021000025A/es unknown
- 2021-02-03 CL CL2021000294A patent/CL2021000294A1/es unknown
- 2021-02-12 US US17/174,826 patent/US11542264B2/en active Active
- 2021-02-25 ZA ZA2021/01273A patent/ZA202101273B/en unknown
- 2021-03-03 CO CONC2021/0002898A patent/CO2021002898A2/es unknown
- 2021-03-03 EC ECSENADI202114902A patent/ECSP21014902A/es unknown
-
2023
- 2023-07-13 US US18/221,694 patent/US20240199617A1/en active Pending
- 2023-08-02 CY CY20231100387T patent/CY1126144T1/el unknown
-
2024
- 2024-02-29 US US18/591,531 patent/US20250034145A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24647B1 (es) | Moduladores del receptor nmda heteroaromático | |
| ECSP24026455A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| CL2018002505A1 (es) | Inhibidores del envejecimiento proteico-proteico wdr5 | |
| CL2016001595A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6. | |
| CR20140085A (es) | Inhibidores de pde10 de pirimidina | |
| NZ713762A (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| MX380777B (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| CR20150425A (es) | Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes | |
| CY1118848T1 (el) | Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης | |
| MX2019000980A (es) | Compuestos y composiciones y usos de los mismos. | |
| CO7280468A2 (es) | Antagonistas del receptor de 5-ht3 | |
| MY187423A (en) | 4-oxo-3,4-dihydro-1,2,3-benzotriazine derivatives as modulators of gpr139 | |
| UY37774A (es) | Compuestos 5-cianoindol sustituidos y usos de los mismos | |
| CU20200041A7 (es) | Amidas de imidazopiridina sustituidas | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| PH12016501863A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| PH12016501993A1 (en) | Heteroaromatic compounds and their use as dopamine d1 ligands | |
| MX2016010529A (es) | Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6). | |
| MX2019000982A (es) | Compuestos y composiciones y usos de los mismos. | |
| CL2020001093A1 (es) | Proceso para preparar el benzotiofen-2-il boronato. | |
| CY1121352T1 (el) | Καινοφανες παραγωγο οξιμης χρωμονης και η χρηση του ως αλλοστερικου ρυθμιστη των μεταβοτροπικων υποδοχεων γλουταμικου | |
| MX2016015767A (es) | Compuestos para el tratamiento de convulsiones y otros trastornos y condiciones del sistema nervioso central. | |
| GT201400168A (es) | Agonistas de mglu 2/3 | |
| ECSP14013268A (es) | Inhibidores de pde10 de pirimidina |